Clinical Trial Update: Study of LY3537982 in Cancer Patients With a Specific Genetic Mutation (KRAS G12C) [Phase 1, Phase 2]

View source ↗

Summary

This clinical trial update reports Eli Lilly's KRAS G12C inhibitor LY3537982 is being studied in Phase 1/2 trials across multiple KRAS G12C-mutant cancers and i…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Biliary Tract Cancer
• Colorectal Cancer
• Endometrial Cancer
• Non-small Cell Lung Cancer
• Ovarian Cancer
• Pancreatic Cancer

Drugs mentioned

• LY3537982

Snippet

Sponsor: Eli Lilly and Company | Conditions: Carcinoma, Non-Small-Cell Lung, Colorectal Neoplasms | Phase 1, Phase 2 | Status: RECRUITING